Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy

Journal of Neuroendocrinology

Volumn 20, Issue 1, 2008, Pages 104-109

  Schaefer, S ^a   Vogt, T ^b   Nowak, T ^c   Kann, P H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Pharmacia GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARGININE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; ENTACAPONE; GONADORELIN; GONADOTROPIN; GROWTH HORMONE; HYPOPHYSIS HORMONE; LISURIDE; PERGOLIDE; PRAMIPEXOLE; PROTIRELIN; RELEFACT; SELEGILINE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; THYROID HORMONE; THYROTROPIN;

ACTION POTENTIAL; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HORMONAL REGULATION; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS FUNCTION; HYPOPROLACTINEMIA; IDIOPATHIC DISEASE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; CORTICOTROPHS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DOPAMINE AGENTS; FOLLICLE STIMULATING HORMONE; GONADOTROPHS; GROWTH HORMONE; HUMANS; HYDROCORTISONE; LACTOTROPHS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PARKINSON DISEASE; PITUITARY GLAND; PROLACTIN; SOMATOTROPHS; THYROID HORMONES; THYROTROPIN; TIME FACTORS;

EID: 36949005624     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2007.01622.x     Document Type: Article

References (41)

1. Sandyk R, Iacono RP, Bamford CR. The hypothalamus in Parkinson's disease. Ital J Neurol Sci 1987; 8: 227-234.
2. Vogel HP, Ketsche R. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy. J Neurol 1986; 233: 149-152.
3. Martignoni E, Horowski R, Liuzzi A, Costa A, Dallabonzana D, Cozzi R, Attanasio R, Rainer E, Nappi G. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: A double-blind study versus placebo. Clin Neuropharmacol 1996; 19: 72-80.
4. Franceschi M, Camerlengo M, Perego L, Bottacci E, Truci G, Mamoli A. Tuberoinfundibular dopaminergic function in Parkinson's disease. Eur Neurol 1988; 28: 117-119.
5. Martinez-Campos A, Giovannini P, Novelli A, Cocchi D, Saraceni T, Muller EE. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease. Acta Endocrinol Copenh 1982; 99: 344-351.
6. Bonuccelli U, Piccini P, Napoletano A, Cagnacci A, Paletti AM, Melis GB, Muratorio A. Reduced luteinizing hormone secretion in women with Parkinson's disease. J Neural Transm 1990; 2: 225-231.
7. Lundberg PO. Blood levels of FSH, LH, TSH, and GH in Parkinsonian patients before and during L-dopa treatment. Acta Neurol Scand 1972; 48: 427-432.
8. Volpi R, Caffarra P, Scaglioni A, Maestri D, Chiodera P, Coiro V. Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease. J Neural Transm 1994; 7: 1-11.
9. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 1991; 238: 19-22.
10. Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL. A study of dopaminergic sensitivity in Parkinson's disease: Comparison in 'de novo' and levodopa-treated patients. Clin Neuropharmacol 1996; 19: 420-427.
11. Volpi R, Caffarra P, Scaglioni A, Boni S, Saginario A, Chiodera P, Coiro V. Defective 5-HT1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. J Clin Endocrinol Metab 1997; 35: 79-83.
12. Murri L, Iudice A, Muratorio A, Polleri A, Barreca T, Murialdo G. Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. Eur Neurol 1980; 19: 198-206.
13. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edingburgh: E & S Livingstone, 1969: 152-157.
14. Kaptein EM, Kletzky OA, Spencer CA, Nicoloff JT. Effects of prolonged dopamine infusion on anterior pituitary function in normal males. J Clin Endocrinol Metab 1980; 51: 488-491.
15. Bansal S, Lee LA, Woolf PD. Dopaminergic regulation of growth hormone (GH) secretion in normal man: Correlation of L-dopa and dopamine levels with the GH response. J Clin Endocrinol Metab 1981; 53: 301-306.
16. Leebaw WF, Lee LA, Woolf PD. Dopamine affects basal and augmented pituitary hormone secretion. J Clin Endocrinol Metab 1978; 47: 480-487.
17. Bansal S, Lee LA, Woolf PD. Dopaminergic modulation of arginine mediated growth hormone and prolactin release in man. Metabolism 1981; 30: 649-653.
18. Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO. Role of dopamine in the regulation of growth hormone secretion: Dopamine and bromocriptine augment growth hormone (GH) releasing hormone-stimulated GH secretion in man. J Clin Endocrinol Metab 1987; 64: 1136-1141.
19. Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992; 51: 541-548.
20. Bazan MC, Barontini M, Domene H, Stefano FJ, Bergada C. Effects of α-bromoergocrytine on pituitary hormone secretion in children. J Clin Endocrinol Metab 1981; 52: 314-318.
21. Hanew K, Sato S, Sasaki A, Goh M, Shimizu Y, Yoshinaga K. The dopaminergic regulation of plasma growth hormone secretion in normal subjects. Tohoku J Exp Med 1986; 148: 151-158.
22. Greenspan SL, Sparrow D, Rowe JW. Dopaminergic regulation of gonadotropin and thyrotropin hormone secretion is altered with age. Horm Res 1991; 36: 41-46.
23. Hyyppa MT, Langvik VA, Rinne UK. Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine. J Neural Transm 1978; 42: 151-157.
24. Shaw KM, Lees AJ, Franks S, Daggett P, Thompson BD, Stern GM. Endocrine aspects of bromocriptine therapy in Parkinsonism. J Neural Transm 1978; 43: 153-160.
25. Malarkey WB, Cyrus J, Paulson GW. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. J Clin Endocrinol Metab 1974; 39: 229-235.
26. Schopohl J, Losa M, Konig A, Muller OA, Stalla GK, von Werder K. Combined pituitary function-test with four hypothalamic releasing hormones. Klin Wochenschr 1986; 64: 314-318.
27. Cooper DS, Jacobs LS. Apomorphine inhibits the prolactin but not the TSH response to thyrotropin releasing hormone. J Clin Endocrinol Metab 1977; 44: 404-407.
28. Bansal SA, Lee LA, Woolf PD. Dopaminergic stimulation and inhibition of growth hormone secretion in normal man: Studies of the pharmacologic specifity. J Clin Endocrinol Metab 1981; 53: 1273-1277.
29. Lal S, Nair NP, Thavundayil JX, Tawar V, Quirion R, Guyda H. Stereospecifity of the dopamine receptor mediating the growth hormone response to apomorphine in man. J Neural Transm 1991; 85: 157-164.
30. Chihara K, Kashio Y, Kita T, Okimura Y, Kaji H, Abe H, Fujita T. L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 1986; 62: 466-473.
31. Friess E, Kuempfel T, Winkelmann J, Schmid D, Uhr M, Rupprecht R, Holsboer F, Trenkwalder C. Increased growth hormone response to apomorphine in Parkinson's disease compared with multiple system atrophy. Arch Neurol 2001; 58: 241-246.
32. Parkes JD, Marsden CD, Donaldson I, Galea-Debono A, Walters J, Kennedy G, Asselman P. Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1976; 39: 184-193.
33. Cavagnini F, Peracchi M, Scotti G, Raggi U, Pontiroli AE, Bana R. Effect of L-dopa administration on growth hormone secretion in normal subjects and parkinsonian patients. J Endocrinol 1972; 54: 425-433.
34. Thorner MO, Ryan SM, Wass JA, Jones A, Bouloux P, Williams S, Besser GM. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab 1978; 47: 372-378.
35. Janzik HH, Heller S. Serum gonadotropic level under the medication L-dopa. Arzneimittelforschung 1974; 24: 1084-1085.
36. Polleri A, Carolei A, Rolandi E, Masturbo P, Meco G, Agnoli A. Changes in pituitary hormones serum levels in bromocryptine-treated parkinsonian patients. Neuropsychobiology 1977; 3: 42-48.
37. Huseman CA, Kugler JA, Schneider IG. Mechanism of dopaminergic suppression of gonadotropin secretion in men. J Clin Endocrinol Metab 1980; 51: 209-214.
38. Pehrson JJ, Jaffee WL, Vaitukaitis JL. Effect of dopamine on gonadotropin-releasing hormone-induced gonadotropin secretion in postmenopausal women. J Clin Endocrinol Metab 1983; 56: 889-892.
39. Jezova D, Vigas M. Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man. Psychoneuroendocrinology 1988; 13: 479-485.
40. Wilcox CS, Aminoff MJ, Millar JG, Keenan J, Kremer M. Circulating levels of corticotrophin and cortisol after infusions of L-dopa, dopamine and noradrenaline, in man. Clin Endocrinol (Oxf) 1975; 4: 191-198.
41. Rabey JM, Vardi Y, Ravid R, Ayalon D. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated Parkinsonian patients. Horm Res 1981; 15: 78-87.